DR. JAMES LOUIS SCHALLER, M.D.
Psychiatric in Naples, FL
License number
Florida ME86096
Category
Psychiatric
Type
Child & Adolescent Psychiatry
Address
Address
5150 N Suite #305, Naples, FL 34103
Phone
(239) 263-0133
(239) 263-6760 (Fax)
(239) 631-2346 (Fax)
(239) 263-6760 (Fax)
(239) 631-2346 (Fax)
Personal information
See more information about JAMES LOUIS SCHALLER at radaris.comName
Address
Phone
7820 Canterbury Ln, Plantation, FL 33324
850 Vermont Ave E, New Port Richey, FL 34653
11300 3Rd St E #2, Saint Petersburg, FL 33706
11945 Boardwalk Dr, Orlando, FL 32826
10355 Paradise Blvd #213, Saint Petersburg, FL 33706
Professional information
See more information about JAMES LOUIS SCHALLER at trustoria.com
Dr. James L Schaller, Naples FL - MD (Doctor of Medicine)
Dr. James L Schaller, Naples FL - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
5150 Tamiami Trl N SUITE 305, Naples 34103
(239) 263-0133 (Phone)
(239) 263-0133 (Phone)
Certifications:
Psychiatry, 2000
Languages:
English
Education:
Medical School
Medical College Of Pennsylvania
Graduated: 1991
Eastern Pennsylvania Psychiatric Institute
Graduated: 1996
Medical College Of Pennsylvania
Graduated: 1991
Eastern Pennsylvania Psychiatric Institute
Graduated: 1996
Background:
Sanction: 1 time(s)
Owner, James Schaller, Md
Owner, James Schaller, Md
Position:
Owner at James Schaller, MD
Location:
Naples, Florida Area
Industry:
Medical Practice
Work:
James Schaller, MD
-
Owner
Topical Formulations For The Treatment Of Depression With S Adenosyl Methionine
Topical Formulations For The Treatment Of Depression With S Adenosyl Methionine
US Patent:
8263574, Sep 11, 2012
Filed:
Sep 29, 2004
Appl. No.:
10/954626
Inventors:
James L. Schaller - Naples FL, US
Ben Briggs - Coatesville PA, US
Ben Briggs - Coatesville PA, US
International Classification:
A61K 31/7076, A61K 31/455, A61K 31/4415
US Classification:
514 46, 514 45, 514350, 514356
Abstract:
Disclosed herein are topical formulations for treating depression with S adenosyl methionine (SAM-e) The topical formulations contain at least 35% wt/wt of SAM-e partially dissolved in aqueous and lipophilic phases of an emulsion and the emulsion is stable from separation of phases for a period of at least 30 days despite the high concentration of SAM-e. Also provided are methods for making such compositions and methods of treating depression using the same.